Navigation Links
MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition
Date:11/16/2009

GAITHERSBURG, Md., Nov. 16 /PRNewswire/ -- MedImmune today announced the winners of a research abstract competition highlighting the work of the next generation of scientific leaders in respiratory disease, inflammation and autoimmunity (RIA). Students and postdoctoral fellows from across the country were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, a leading biologics company headquartered in Gaithersburg, Maryland.

The competition's ten finalists convened today at the company's headquarters to present their research to an expert panel of MedImmune judges. The three winners were announced at the awards ceremony following the presentations.

First prize of $2,000 was awarded to Eric Boilard, a postdoctoral student of Harvard Medical School and Brigham & Women's Hospital for his research on the role of platelets in amplifying inflammation in arthritis. "I would like to thank everyone at MedImmune for sponsoring this competition. I am honored to be a winner and grateful for the opportunity to receive such great feedback from renowned individuals on the panel."

Second and third prizes of $1,000 and $500 were awarded to Irving Allen of University of North Carolina and Kerstin Kiefer of Boston University School of Medicine, respectively.

"We saw some very high-caliber preclinical approaches," said Anthony J. Coyle, Ph.D., vice president, research and development and head, respiratory, inflammation and autoimmunity research at MedImmune. "Their research could pave the way for further understanding of the mechanism of these diseases, and could potentially help in the development of new therapies."

"We are committed to investing in future scientists and promoting health and science education," said Bahija Jallal, Senior Vice President of Research and Development at MedImmune. "We were impressed with today's presentations, and congratulate all of the ten finalists on their thought-provoking work."

The competition was open to graduate students and postdoctoral fellows worldwide. The expert panel of judges evaluated the abstracts according to the following criteria: scientific rationale, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

Notes to Editors:

    First Place:      Harvard Medical School, Brigham & Women's Hospital
                      postdoctoral student Eric Boilard. The title of his
                      abstract is "Platelets amplify inflammation in arthritis
                      via collagen-dependent microparticle production."

    Second Place:     University of North Carolina at Chapel Hill postdoctoral
                      student Irving Allen. The title of his abstract is
                      "NLRX1 is a regulator of the innate immune response to
                      influenza A virus infection."

    Third Place:      Boston University School of Medicine postdoctoral
                      student Kerstin Kiefer. The title of her abstract is
                      "The role of TAM receptor tyrosine kinases in B cell
                      activation and differentiation."

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

Media Contact:

    Perla Copernik
    (301) 398-4952

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. MedImmune Expands Scientific and Engineering Leadership
8. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
9. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
10. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
11. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that Mr. Michael Merges, ... upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, on ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... the revolutionary Active Brake Technology (ABT), an innovative braking system that allows skaters ... Brake Technology addresses one of the biggest concerns of beginner and intermediate skaters ...
(Date:1/17/2017)... Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness ... who choose to lurk in the corners and commit the crime of stalking, a very ... use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... Safe Rx LLC and Good Day Pharmacy, ... Loveland, Colorado , today announced the availability ... Day locations.     "Patients with prescriptions prone ... storage," said Milton Cohen , President & CEO ... a cup of coffee, you can protect your children ...
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
Breaking Medicine Technology: